LABP - Landos Biopharma, Inc. Stock Price, Fair Value and News

$22.93

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LABP Price Action

Last 7 days

0.6%

Last 30 days

3.7%

Last 90 days

301.3%

Trailing 12 Months

7648.3%

LABP RSI Chart

LABP Valuation

Market Cap

71.7M

Price/Earnings (Trailing)

-2.89

Price/Sales (Trailing)

3.88

EV/EBITDA

-1.77

Price/Free Cashflow

-3.45

LABP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LABP Fundamentals

LABP Revenue

Revenue (TTM)

18.0M

LABP Earnings

Earnings (TTM)

-24.8M

Earnings Growth (Yr)

-47.45%

Earnings Growth (Qtr)

-45.4%

LABP Profitability

EBT Margin

-137.77%

Return on Equity

-107.1%

Return on Assets

-82.95%

Free Cashflow Yield

-29.03%

LABP Investor Care

Buy Backs (1Y)

84.37%

Diluted EPS (TTM)

-3.99

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	72.0M	36.0M	18.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Landos Biopharma, Inc.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

CEO	Mr. Gregory Oakes
WEBSITE	https://landosbiopharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	22

Landos Biopharma, Inc. Frequently Asked Questions

What is the ticker symbol for Landos Biopharma, Inc.? What does LABP stand for in stocks?

LABP is the stock ticker symbol of Landos Biopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Landos Biopharma, Inc. (LABP)?

As of Thu May 23 2024, market cap of Landos Biopharma, Inc. is 71.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LABP stock?

You can check LABP's fair value in chart for subscribers.

Is Landos Biopharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether LABP is over valued or under valued. Whether Landos Biopharma, Inc. is cheap or expensive depends on the assumptions which impact Landos Biopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LABP.

What is Landos Biopharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 23 2024, LABP's PE ratio (Price to Earnings) is -2.89 and Price to Sales (PS) ratio is 3.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LABP PE ratio will change depending on the future growth rate expectations of investors.